GAITHERSBURG, Md., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its Chief Executive Officer, Vipin Garg, Ph.D., and Chief Medical Officer, Scott Harris, M.D., will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference:
Conference: | H.C. Wainwright 8thAnnual MASH Virtual Conference |
Presenters: | Vipin Garg, Ph.D., Chief Executive Officer |
Scott Harris, M.D., Chief Medical Officer | |
Date/Time: | Monday, October 7, 2024, at 11:30 a.m. EDT |
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
This email address is being protected from spambots. You need JavaScript enabled to view it.
Julia Weilman
Burns McClellan
Phone: 646-732-4443
This email address is being protected from spambots. You need JavaScript enabled to view it.
This press release was published by a CLEAR® Verified individual.
Last Trade: | US$4.40 |
Daily Change: | -0.34 -7.17 |
Daily Volume: | 8,955,895 |
Market Cap: | US$356.880M |
June 26, 2025 June 13, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load